Date: 28-Mar-2020

GenScript ProBio Congratulates XlifeSciences On The Start Of TAEST16001 Early Phase Clinical Trial

NANJINGChinaMarch 27, 2020 /PRNewswire/ -- GenScript USA Inc. XlifeSciences, a partner of GenScript ProBio (GenScript's CDMO segment) announced that the early phase clinical trial of TAEST16001 project has been started. GenScript ProBio extends congratulations on this.

This clinical trial project is China's first TCR-T project targeted at solid tumor therapy, marking a milestone in immunotherapy in China. In 2019, XlifeSciences entrusted TCR-T products with complete independent intellectual property rights to GenScript ProBio. It is the first cooperation project between the parties, where GenScript ProBio works on plasmid and virus process development and clinical manufacturing and will be further responsible for commercial manufacturing.

"We congratulate XLifeSciences on the successful launch of TAEST16001 early phase clinical trial, which marks a milestone in the industry," said Dr. Brian Min, CEO of GenScript ProBio. "We are honored to offer technology and manufacturing support in such a meaningful project. With a one-stop high-quality plasmid and virus platform, GenScript ProBio facilitates XLifeSciences to complete all pre-clinical CMC research for IND filing. We will continue to follow up on the clinical trial. We wish that the clinical project proceeds smoothly so as to relieve patients from pain as soon as possible. We are optimistic about the prospects of the project. As China's first company that has built the plasmid facility for gene and cell therapy, GenScript ProBio has well-established technological platform and quality system, and is capable of providing quality services to more customers.

About Xiangxue Life Sciences

Xiangxue Life Sciences (XLifeSc) is a biopharmaceutical company focused on TCR-based therapies for cancer. Our main proprietary technological platforms are composed of: (1) High Affinity T Cell Activation Core (HATac); (2) TCR Affinity Enhancing Specific T Cell Therapy (TAEST). The two platforms have been fully developed to the clinic-ready stage. As a result, an independently-owned intellectual property portfolio has been constructed which spans across the whole spectrum of TCR-related technologies including the identification of tumor-specific antigens, antigen-specific TCRs, and the optimization of antigen-specific TCRs in terms of affinity and stability, etc. To date, many domestic and PCT applications have been filed.